

**Table S2** General demographic and clinical data of the study population

	Clinicopathological factors	BC group ( <i>n</i> = 22)	NC group ( <i>n</i> = 20)	<i>p</i> value
Training cohort	Age	62.00 ± 15	63.50 ± 10	0.801 <sup>a</sup>
	Gender	Male 20 (90.90%)	Male 19 (95.00%)	1.000 <sup>b</sup>
		Female 2 (9.10%)	Female 1 (5.00%)	
	Cigarette smokers	13 (59.09%)	8 (40%)	0.217 <sup>c</sup>
	Tumor stage	NMIBC 19 (86.36%)		
		MBIC 3 (13.64%)		
	Tumor grade	Low 15 (68.18%)		
		High 7 (31.82%)		
	Clinicopathological factors	BC group ( <i>n</i> = 33)	NC group ( <i>n</i> = 23)	<i>p</i> value
Validation cohort	Age	65.00 ± 16	65.00 ± 11	0.927 <sup>a</sup>
	Gender	Male 28 (84.85%)	Male 17 (73.91%)	0.331 <sup>b</sup>
		Female 5 (15.15%)	Female 6 (26.09%)	
	Cigarette smokers	19 (57.58%)	10 (43.48%)	0.299 <sup>c</sup>
	Tumor stage	NMBIC 22 (66.67%)		
		MBIC 11 (33.33%)		
	Tumor grade	Low 14 (42.42%)		
		High 19 (57.58%)		

The data are shown as median ± interquartile range, BC bladder cancer, NC normal controls, NMIBC non-muscle-invasive bladder cancer, MIBC muscle-invasive bladder cancer, a Mann-Whitney U test, b Fisher's exact test, c Chi-square test